转移性食管鳞癌的药物治疗进展
Advances in pharmacological treatment of metastatic esophageal squamous cell carcinoma
张淑娟 1杨晓玲 1王惠杰2
作者信息
- 1. 新疆维吾尔自治区喀什地区第二人民医院肿瘤科,喀什 844000
- 2. 复旦大学附属肿瘤医院肿瘤内科 复旦大学上海医学院肿瘤学系,上海 200032
- 折叠
摘要
转移性食管鳞癌预后差,免疫检测点抑制剂、靶向表皮生长因子受体(EGFR)以及抗血管生成治疗的进展改善了疾病预后.免疫治疗或免疫化疗已成为新的治疗选择.靶向EGFR单抗可能在免疫耐药后具有重要作用,而EGFR单抗联合免疫化疗可望进一步提高一线治疗效果.EGFR酪氨酸激酶抑制剂(TKIs)在二线治疗中显示出较高的疾病控制率.靶向抗血管生成治疗联合化疗在一线及二线治疗中显示较好的疗效,而免疫化疗联合血管内皮生长因子受体(VEGFR)TKIs可望进一步改善疾病预后.
Abstract
The poor prognosis of relapsed and metastatic esophageal squamous cell carcinoma(mESCC)has been improved with advances in immune checkpoint inhibitors(ICIs),targeted epidermal growth factor receptor(EGFR)and anti-angiogenic therapy.Currently immunotherapy or immunochemotherapy has become a new treatment option.Targeted EGFR monoclonal antibody may play an important role in immunoresistant diseases,and also in first-line treatment when combined with immunochemotherapy.EGFR tyrosine kinase inhibitors(TKIs)shows a higher rate of disease control in second-line treatment.Targeted anti-angiogenic therapy combined with chemotherapy has shown efficacy in both first-line and second-line treatments,while immunochemotherapy combined with vascular endothelial growth factor receptor(VEGFR)TKIs is expected to further improve the prognosis of mESCC.
关键词
转移性食管鳞癌/免疫治疗/靶向治疗/表皮生长因子受体/抗血管生成治疗Key words
Metastatic esophageal squamous cell carcinoma/Immunotherapy/Targeted therapy/Epidermal growth factor receptor/Anti-angiogenic therapy引用本文复制引用
基金项目
上海市"科技创新行动计划"国内科技合作项目(22015831900)
出版年
2024
NETL
NSTL
万方数据